Biofrontera Warrants Net Worth
Biofrontera Warrants Net Worth Breakdown | BFRIW |
Biofrontera Warrants Net Worth Analysis
Biofrontera Warrants' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Biofrontera Warrants' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Biofrontera Warrants' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Biofrontera Warrants' net worth analysis. One common approach is to calculate Biofrontera Warrants' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Biofrontera Warrants' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Biofrontera Warrants' net worth. This approach calculates the present value of Biofrontera Warrants' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Biofrontera Warrants' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Biofrontera Warrants' net worth. This involves comparing Biofrontera Warrants' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Biofrontera Warrants' net worth relative to its peers.
Enterprise Value |
|
To determine if Biofrontera Warrants is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biofrontera Warrants' net worth research are outlined below:
| Biofrontera Warrants is way too risky over 90 days horizon | |
| Biofrontera Warrants has some characteristics of a very speculative penny stock | |
| Biofrontera Warrants appears to be risky and price may revert if volatility continues | |
| Biofrontera Warrants has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 34.07 M. Net Loss for the year was (20.13 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biofrontera Warrants generates negative cash flow from operations | |
| Biofrontera Warrants has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Biofrontera Inc. Closes a 4.2 Million Senior Secured Convertible Note |
Project Biofrontera Warrants' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.80) | (0.84) | |
| Return On Capital Employed | (2.30) | (2.19) | |
| Return On Assets | (0.72) | (0.76) | |
| Return On Equity | (4.20) | (3.99) |
When accessing Biofrontera Warrants' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Biofrontera Warrants' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biofrontera Warrants' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Biofrontera Warrants' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Biofrontera Warrants. Check Biofrontera Warrants' Beneish M Score to see the likelihood of Biofrontera Warrants' management manipulating its earnings.
Evaluate Biofrontera Warrants' management efficiency
The company has return on total asset (ROA) of (0.4024) % which means that it has lost $0.4024 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4941) %, meaning that it generated substantial loss on money invested by shareholders. Biofrontera Warrants' management efficiency ratios could be used to measure how well Biofrontera Warrants manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.84 in 2024. Return On Capital Employed is likely to climb to -2.19 in 2024. At this time, Biofrontera Warrants' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 6.4 M in 2024, whereas Other Current Assets are likely to drop slightly above 4.7 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.10 | 3.25 | |
| Tangible Book Value Per Share | 1.40 | 1.47 | |
| Enterprise Value Over EBITDA | (0.45) | (0.47) | |
| Price Book Value Ratio | 0.89 | 0.85 | |
| Enterprise Value Multiple | (0.45) | (0.47) | |
| Price Fair Value | 0.89 | 0.85 | |
| Enterprise Value | 8.3 M | 7.9 M |
The operational strategies employed by Biofrontera Warrants management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Revenue 35.2 M | Quarterly Revenue Growth 0.34 | Revenue Per Share 11.573 | Return On Equity (1.49) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biofrontera Warrants insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biofrontera Warrants' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biofrontera Warrants insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lanckriet Heikki over a month ago Insider Trading |
Biofrontera Warrants Earnings per Share Projection vs Actual
Biofrontera Warrants Corporate Management
| Jon MBA | Vice Affairs | Profile | |
| Daniel JD | General Compliance | Profile | |
| Mark Baldyga | Vice Marketing | Profile | |
| Alycia Torres | Vice Administration | Profile | |
| Samantha Widdicombe | Senior Communications | Profile | |
| Eugene III | Chief Officer | Profile |
Additional Tools for Biofrontera Stock Analysis
When running Biofrontera Warrants' price analysis, check to measure Biofrontera Warrants' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera Warrants is operating at the current time. Most of Biofrontera Warrants' value examination focuses on studying past and present price action to predict the probability of Biofrontera Warrants' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera Warrants' price. Additionally, you may evaluate how the addition of Biofrontera Warrants to your portfolios can decrease your overall portfolio volatility.